Asthma Drugs Market in the US 2015-2019

1
Asthma Drugs Market in the US 2015-2019
Single User License - 3000 Site User License -
3500 Corporate User License - 4500 Publication
Date - Jun 2015 Pages - 103 To know more
details, email to debora_at_reportstack.com
2
Summary

• Asthma is a disease that affects the lungs and is
  characterized by wheezing, coughing,
  breathlessness, and chest tightness. It is a
  chronic ailment of the respiratory tract, which
  is caused by the obstruction of the flow of air
  and bronchospasms, where the muscles around the
  respiratory tract swell up. The disease is
  believed to be caused by genetic as well as
  environmental factors. The American Academy of
  Allergy Asthma and Immunology classifies asthma
  under four categories exercise-induced asthma,
  allergic asthma, occupational asthma, and
  childhood asthma. The Asthma and Allergy
  Foundation of America classifies asthma into two
  categories allergic asthma and non-allergic
  asthma. It is an incurable disease but can be
  controlled with the help of diagnosis at the
  right time, followed by regular therapy.

3
Key vendors
AstraZeneca F. Hoffmann-La Roche
GlaxoSmithKline Merck
4
Other Prominent Vendors
Abbott Laboratories Addex Therapeutics
Alkermes AstraZeneca Aurobindo Pharma
Avanir Pharmaceuticals Cerecor Chugai
Pharmaceutical Dart NeuroScience  Dr. Reddy's
Laboratories Edgemont Pharmaceuticals 
E-Therapeutics Euthymics Evotec, etc
5
Key Questions Answered in this Report
What will the market size be in 2019 and what
will the growth rate be? What are the key
market trends? What is driving this market?
What are the challenges to market growth? Who
are the key vendors in this market space? What
are the market opportunities and threats faced by
the key vendors? What are the strengths and
weaknesses of the key vendors?
6
If you are interested...
Contact Debora White Email
debora_at_reportstack.com Ph1-888-789-6604 http/
/www.reportstack.com